1. Volume 75, Issue 2, Pages 274-282 (February 2019)
Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial 
Henry D. Mitcheson, Suvajit Samanta, Karen Muldowney, Cathy A. Pinto, Beatriz de A. Rocha, Stuart Green, Nathan Bennett, Paul N. Mudd, Tara L. Frenkl 
European Urology 
Volume 75, Issue 2, Pages (February 2019)
DOI: /j.eururo
Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions

2. Fig. 1 Patient disposition. ER=extended release.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions

3. Fig. 2
Change from baseline in average daily number of (A) micturitions, (B) urgency episodes, (C) urgency urinary incontinence episodes, and (D) total incontinence episodes over 8 wk (part 1; least square mean±95% confidence interval). BL=baseline; ER=extended release; LS=least square.
European Urology  , DOI: ( /j.eururo )
Copyright © 2018 Merck Sharp & Dohme Corp and The Authors Terms and Conditions